Terms: = Pancreatic cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS AND Treatment
22 results:
1. A multicenter, randomized phase 2 study to establish combinations of cbp501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract] [Full Text] [Related]
2. Establishment and Molecular Characterization of Two Patient-Derived pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for treatment Response.
Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
[TBL] [Abstract] [Full Text] [Related]
3. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
van Riet J; van de Werken HJG; Cuppen E; Eskens FALM; Tesselaar M; van Veenendaal LM; Klümpen HJ; Dercksen MW; Valk GD; Lolkema MP; Sleijfer S; Mostert B
Nat Commun; 2021 Jul; 12(1):4612. PubMed ID: 34326338
[TBL] [Abstract] [Full Text] [Related]
4. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer.
Ono H; Kato T; Murase Y; Nakamura Y; Ishikawa Y; Watanabe S; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Akiyama Y; Tanaka S; Ito H; Tanabe M
Sci Rep; 2021 May; 11(1):10078. PubMed ID: 33980911
[TBL] [Abstract] [Full Text] [Related]
5. Celiac Plexus Block Complications: A Case Report and Review of the Literature.
Gupta R; Madanat L; Jindal V; Gaikazian S
J Palliat Med; 2021 Sep; 24(9):1409-1412. PubMed ID: 33395560
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
[TBL] [Abstract] [Full Text] [Related]
7. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription.
Liu S; Zheng Y; Zhang Y; Zhang J; Xie F; Guo S; Gu J; Yang J; Zheng P; Lai J; Yin L; Wang H
Theranostics; 2020; 10(23):10634-10651. PubMed ID: 32929371
[No Abstract] [Full Text] [Related]
8. Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth.
Lei MZ; Li XX; Zhang Y; Li JT; Zhang F; Wang YP; Yin M; Qu J; Lei QY
Signal Transduct Target Ther; 2020 May; 5(1):70. PubMed ID: 32467562
[TBL] [Abstract] [Full Text] [Related]
9. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma.
Huang H; Zou Y; Zhang H; Li X; Li Y; Deng X; Sun H; Guo Z; Ao L
Transl Res; 2020 May; 219():30-44. PubMed ID: 32119844
[TBL] [Abstract] [Full Text] [Related]
10. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
11. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a cbp/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
Kimura K; Ikoma A; Shibakawa M; Shimoda S; Harada K; Saio M; Imamura J; Osawa Y; Kimura M; Nishikawa K; Okusaka T; Morita S; Inoue K; Kanto T; Todaka K; Nakanishi Y; Kohara M; Mizokami M
EBioMedicine; 2017 Sep; 23():79-87. PubMed ID: 28844410
[TBL] [Abstract] [Full Text] [Related]
12. The G2 checkpoint inhibitor cbp-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.
Iwata T; Uchino T; Koyama A; Johmura Y; Koyama K; Saito T; Ishiguro S; Arikawa T; Komatsu S; Miyachi M; Sano T; Nakanishi M; Shimada M
PLoS One; 2017; 12(5):e0178221. PubMed ID: 28558031
[TBL] [Abstract] [Full Text] [Related]
13. Experience with surgical treatment of retroperitoneal soft tissue sarcomas at a university hospital in Thailand.
Sriussadaporn S; Sriussadaporn S; Pak-art R; Kritayakirana K; Prichayudh S; Samorn P
J Med Assoc Thai; 2014 Jun; 97(6):598-614. PubMed ID: 25137877
[TBL] [Abstract] [Full Text] [Related]
14. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
[TBL] [Abstract] [Full Text] [Related]
15. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma.
Maftouh M; Belo AI; Avan A; Funel N; Peters GJ; Giovannetti E; Van Die I
Oncotarget; 2014 Jul; 5(14):5335-49. PubMed ID: 24977327
[TBL] [Abstract] [Full Text] [Related]
16. A perylene derivative regulates HIF-1α and Stat3 signaling pathways.
Chen H; Guan Y; Yuan G; Zhang Q; Jing N
Bioorg Med Chem; 2014 Feb; 22(4):1496-505. PubMed ID: 24485121
[TBL] [Abstract] [Full Text] [Related]
17. cbp-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT.
Pramanik KC; Fofaria NM; Gupta P; Srivastava SK
Mol Cancer Ther; 2014 Mar; 13(3):687-98. PubMed ID: 24419059
[TBL] [Abstract] [Full Text] [Related]
18. A novel fusion protein diphtheria toxin-stem cell factor (DT-SCF)-purification and characterization.
Potala S; Verma RS
Appl Biochem Biotechnol; 2010 Nov; 162(5):1258-69. PubMed ID: 20084469
[TBL] [Abstract] [Full Text] [Related]
19. [Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Zhou JX; Hong GB; Xu LY; Xu LF; Chen YT; Jiang RJ; Luo JH
Ai Zheng; 2004 Dec; 23(12):1677-80. PubMed ID: 15601559
[TBL] [Abstract] [Full Text] [Related]
20. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Tsujie M; Nakamori S; Okami J; Hayashi N; Hiraoka N; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Exp Cell Res; 2003 Sep; 289(1):143-51. PubMed ID: 12941612
[TBL] [Abstract] [Full Text] [Related]
[Next]
